Resultados de la búsqueda 31-40 of 10020 for 不留痕搜索咨询邮箱：lgooxc@hotmail.com
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that ...
The purpose of this study is to find out more about certain markers of immune suppression in people with kidney tumors (whether the tumors are benign or ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
News. abril 2025. Your abdominal core: Expert shares tips for protecting a part of the body you may not think about April 03, 2025, 04:02 p.m. CDT ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Estar en forma — de estiramientos, flexibilidad, y ejercicio aeróbido a entrenamiento de fuerza y nutrición deportiva.
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...
News · mayo 2025 · abril 2025 · marzo 2025 · febrero 2025 · enero 2025 · diciembre 2024 · noviembre 2024 · octubre 2024.
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
Often a medical history and a physical exam are enough to diagnose many types of tendinopathy. Your healthcare professional may press on the affected joint and ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?